Literature DB >> 16941694

Intrahepatic levels and replicative activity of covalently closed circular hepatitis B virus DNA in chronically infected patients.

Andreas Laras1, John Koskinas, Evangelini Dimou, Ageliki Kostamena, Stephanos J Hadziyannis.   

Abstract

Hepatitis B virus (HBV) covalently closed circular DNA (cccDNA) is responsible for viral persistence in the natural course of chronic HBV infection and during prolonged antiviral therapy and serves as the template for the production of HBV pregenomic RNA (pgRNA), the primary step in HBV replication. In this study, we have developed and applied sensitive and specific quantitative real-time polymerase chain reaction (PCR) assays for the measurement of intrahepatic concentration, pgRNA production, and replicative activity of cccDNA in liver biopsy samples from 34 non-treated patients with chronic hepatitis B (CHB); 12 hepatitis B e antigen (HBeAg)(+) and 22 HBeAg(-). Median copy number for cccDNA was 1.5 per cell and for pgRNA significantly higher, 6.5 copies per cell, with a good correlation between cccDNA and pgRNA levels in all samples. In HBeAg(-) patients, median values of cccDNA and pgRNA levels were 10-fold and 200-fold lower than in HBeAg(+), respectively, reflecting the differences in viral activity and clinical characteristics of the two groups. Furthermore, the replicative activity of intrahepatic cccDNA was significantly lower in HBeAg(-) patients harboring mutant HBV strains than in HBeAg(+) patients: median 3.5 versus 101 pgRNA copies per cccDNA molecule. In conclusion, the levels of both HBV cccDNA, a marker of HBV persistence, and pgRNA, an indicator of viral replication, in the liver of chronically infected patients correlate with viral activity and the phase of HBV infection. The combined measurement of cccDNA and pgRNA levels provides valuable information on the presence and replicative activity of intrahepatic HBV cccDNA.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16941694     DOI: 10.1002/hep.21299

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  68 in total

Review 1.  Metabolism and function of hepatitis B virus cccDNA: Implications for the development of cccDNA-targeting antiviral therapeutics.

Authors:  Ju-Tao Guo; Haitao Guo
Journal:  Antiviral Res       Date:  2015-08-10       Impact factor: 5.970

2.  Current status of antiviral therapy for hepatitis B.

Authors:  Daryl T-Y Lau; Wissam Bleibel
Journal:  Therap Adv Gastroenterol       Date:  2008-07       Impact factor: 4.409

Review 3.  Progress With Developing Use of Gene Editing To Cure Chronic Infection With Hepatitis B Virus.

Authors:  Abdullah Ely; Buhle Moyo; Patrick Arbuthnot
Journal:  Mol Ther       Date:  2016-02-26       Impact factor: 11.454

4.  Hepatitis B virus molecular biology and pathogenesis.

Authors:  R Jason Lamontagne; Sumedha Bagga; Michael J Bouchard
Journal:  Hepatoma Res       Date:  2016-07-01

Review 5.  How to achieve immune control in chronic hepatitis B?

Authors:  Margo J H van Campenhout; Harry L A Janssen
Journal:  Hepatol Int       Date:  2014-09-06       Impact factor: 6.047

6.  T5 Exonuclease Hydrolysis of Hepatitis B Virus Replicative Intermediates Allows Reliable Quantification and Fast Drug Efficacy Testing of Covalently Closed Circular DNA by PCR.

Authors:  Bingqian Qu; Yi Ni; Florian A Lempp; Florian W R Vondran; Stephan Urban
Journal:  J Virol       Date:  2018-11-12       Impact factor: 5.103

7.  Covalently closed-circular hepatitis B virus DNA reduction with entecavir or lamivudine.

Authors:  Scott Bowden; Stephen Locarnini; Ting-Tsung Chang; You-Chen Chao; Kwang-Hyub Han; Robert G Gish; Robert A de Man; Miao Yu; Cyril Llamoso; Hong Tang
Journal:  World J Gastroenterol       Date:  2015-04-21       Impact factor: 5.742

Review 8.  Mechanism of Hepatitis B Virus Persistence in Hepatocytes and Its Carcinogenic Potential.

Authors:  Maura Dandri; Joerg Petersen
Journal:  Clin Infect Dis       Date:  2016-06-01       Impact factor: 9.079

Review 9.  Virus and Host Testing to Manage Chronic Hepatitis B.

Authors:  Grace Lai-Hung Wong; Vincent Wai-Sun Wong; Henry Lik-Yuen Chan
Journal:  Clin Infect Dis       Date:  2016-06-01       Impact factor: 9.079

10.  The role of quantitative hepatitis B serology in the natural history and management of chronic hepatitis B.

Authors:  Tin Nguyen; Paul Desmond; Stephen Locarnini
Journal:  Hepatol Int       Date:  2009-09-18       Impact factor: 6.047

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.